ARTICLE SUMMARY:
Israeli start-up Magenta Medical progresses toward challenging the pLVAD status quo with an early feasibility study of its Elevate device.
Israeli start-up Magenta Medical, led by David Israeli, MD, is making headway toward becoming a disruptive player in the percutaneous left ventricular assist device (pLVAD) market. Today, that market is all but dominated by Abiomed’s (acquired by Johnson & Johnson in a $16.6 billion deal) Impella CP device, but Israeli has reason to believe that Magenta’s Elevate may be able to tip the scales with evidence of strong safety and performance profiles.
